4D Molecular announces 4D-150 license agreement with Otsuka Pharmaceutical

4D Molecular (FDMT) announced a strategic partnership with Otsuka Pharmaceutical to develop and commercialize 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema in the greater Asia-Pacific region including Japan. Together, the companies aim to receive 4D-150 marketing approval and commercialization in major markets globally. 4D-150 is a backbone therapy providing durable benefit in retinal vascular diseases such as wet AMD and DME. Under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases, including wet AMD and DME, in Japan, China, Australia and other Asia-Pacific markets. Otsuka will lead all regulatory and commercialization activities in its licensed territories. 4DMT will continue to lead all Phase 3 clinical activities globally, including within the APAC region. APAC clinical sites in 4FRONT-2, the global Phase 3 study in wet AMD, are expected to open by end of year, with Japan sites expected to open in January 2026. 4DMT will receive an upfront cash payment of $85M and expected cost sharing of at least $50M over the next three years for global development activities. In addition, the company is eligible for up to $336M in potential regulatory and commercial milestone payments and tiered double-digit royalties depending on net sales in Otsuka’s territories. 4DMT retains full development and commercialization rights for 4D-150 outside the APAC region, including the U.S., Latin America and Europe.